books search
books
articles search
articles
Donate
Log In
Log In
to access more features
personal recommendations
Telegram Bot
download history
send to Email or Kindle
manage booklists
save to favorites
Explore
Journals
Contribution
Donate
Litera Library
Donate paper books
Add paper books
Open LITERA Point
Volume 10; Issue 19
Main
Oncotarget
Volume 10; Issue 19
Oncotarget
Volume 10; Issue 19
1
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma
van Herpen, Carla M.L.
,
Agarwala, Sanjiv S.
,
Hauschild, Axel
,
Berking, Carola
,
Beck, J. Thaddeus
,
Schadendorf, Dirk
,
Jansen, Rob
,
Queirolo, Paola
,
Ascierto, Paolo A.
,
Blank, Christian U.
,
Heinrich, Mi
Journal:
Oncotarget
Year:
2019
Language:
english
File:
PDF, 2.35 MB
Your tags:
english, 2019
2
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma
van Herpen, Carla M.L.
,
Agarwala, Sanjiv S.
,
Hauschild, Axel
,
Berking, Carola
,
Beck, J. Thaddeus
,
Schadendorf, Dirk
,
Jansen, Rob
,
Queirolo, Paola
,
Ascierto, Paolo A.
,
Blank, Christian U.
,
Heinrich, Mi
Journal:
Oncotarget
Year:
2019
File:
PDF, 2.35 MB
Your tags:
2019
1
Follow
this link
or find "@BotFather" bot on Telegram
2
Send /newbot command
3
Specify a name for your chatbot
4
Choose a username for the bot
5
Copy an entire last message from BotFather and paste it here
×
×
